After-Hours Stock Movers 10/19: (SESN) (AKRO) (LRN) Higher; (ATIP) (WDFC) Lower (more...)
Get Alerts SESN Hot Sheet
Join SI Premium – FREE
After-Hours Stock Movers:
Sesen Bio (NASDAQ: SESN) 13.9% HIGHER; disclosed: On the morning of October 19, 2021, the US Food & Drug Administration (FDA) granted Sesen Bio, Inc.s (the Company) request for a Type A meeting to discuss the Chemistry, Manufacturing and Controls (CMC) issues raised in the FDAs Complete Response Letter (CRL) regarding the Companys Biologics License Application (BLA) for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (the CMC Type A Meeting). The CMC Type A Meeting has been scheduled for October 29, 2021. During the CMC Type A Meeting, the Company intends to align on a path forward with the FDA related to the CMC issues raised in the CRL.
ATI Physical Therapy (NYSE: ATIP) 13.7% LOWER; Reports Prelim. Q3 Results, Lowers FY Revenue Guidance
WD-40 Co. (NASDAQ: WDFC) 8.9% LOWER; reported Q4 EPS of $0.61, $0.62 worse than the analyst estimate of $1.23. Revenue for the quarter came in at $115.2 million versus the consensus estimate of $117.47 million.
Akero Therapeutics, Inc. (Nasdaq: AKRO) 5.7% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program investigating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH).
Stride Inc. (NYSE: LRN) 5.3% HIGHER; reported Q1 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $400.2 million versus the consensus estimate of $359.48 million. Stride Inc. sees FY2022 revenue of $1.56-1.6 billion, versus the consensus of $1.47 billion.
United Airlines (NASDAQ: UAL) 1.9% HIGHER; reported Q3 EPS of ($1.02), $0.27 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $7.85 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After-hours movers: ANSYS, National CineMedia, and more
- Legend Biotech (LEGN) Announces CARVYKTI Receives Recommendation from FDA Committee for Earlier Treatment of Patients with R/R Multiple Myeloma
- OptiNose (OPTN) Announces XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Create E-mail Alert Related Categories
Special ReportsRelated Entities
After-Hours Movers, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!